Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Precigen ( (PGEN) ) just unveiled an announcement.
On September 3, 2025, Precigen, Inc. announced a loan agreement with Pharmakon Advisors, LP, securing a 5-year senior secured term loan facility of up to $125 million. This non-dilutive financing, with an initial $100 million funded at closing, aims to support the commercialization of PAPZIMEOS, a novel immunotherapy, in the US and potentially expand into international markets. The agreement strengthens Precigen’s financial position, enabling it to pursue pediatric and other HPV-related indications, and is expected to drive significant growth, positioning the company as a leading biopharma innovator.
The most recent analyst rating on (PGEN) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Precigen stock, see the PGEN Stock Forecast page.
Spark’s Take on PGEN Stock
According to Spark, TipRanks’ AI Analyst, PGEN is a Neutral.
Precigen’s overall stock score is driven by strong technical momentum and positive corporate events, offset by weak financial performance and valuation concerns. The FDA approval and supply agreement are significant positives, while financial instability remains a major risk.
To see Spark’s full report on PGEN stock, click here.
More about Precigen
Precigen, Inc. is a biopharmaceutical company focused on developing innovative precision medicines to address challenging diseases with high unmet patient needs. The company is committed to advancing scientific breakthroughs from proof-of-concept to commercialization, with a pipeline that includes therapies in immuno-oncology, autoimmune disorders, and infectious diseases.
Average Trading Volume: 7,376,567
Technical Sentiment Signal: Buy
Current Market Cap: $1.34B
For a thorough assessment of PGEN stock, go to TipRanks’ Stock Analysis page.